NIH study finds Cediranib benefits patients with ASPS

An experimental drug, cediranib, may benefit alveolar soft part sarcoma (ASPS) patients, according a recent clinical […]
Since its inception, the iCureASPS organization has transferred more than a quarter million dollars to keep […]
Dear ASPS Community! This coming weekend in August 2010, Team ASPS will ride in the Pan-Massachusetts […]
The second Annual Knockin’ Down ASPS Event in the memory of Anthony Salisbury (AJ) took place […]
For Alveolar Soft Part Sarcoms patients the use of aggressive surgery, appropriate diagnostic imaging, and long-term surveillance for […]
Dr. Dina Lev, from the Cancer Biology and the Sarcoma Research Center at the University of […]
Cediranib (Recentin, AZD2171) is an inhibitor of VEGF (Vascular Endothelial Growth Factor) receptors. Therefore, the drug […]
This weekend, Team ASPS rode the Pan-Massachusetts Challenge (PMC) for the 6th time. This bike-a-thon crosses […]
On 26 January 2009, we lost Anthony Salisbury (AJ) to ASPS. AJ’s fiancé, family and friends […]